Clinical significance of FBXW7 loss of function in human cancers
- PMID: 35346215
- PMCID: PMC8962602
- DOI: 10.1186/s12943-022-01548-2
Clinical significance of FBXW7 loss of function in human cancers (V体育安卓版)
Abstract (VSports注册入口)
FBXW7 (F-Box and WD Repeat Domain Containing 7) (also referred to as FBW7 or hCDC4) is a component of the Skp1-Cdc53 / Cullin-F-box-protein complex (SCF/β-TrCP). As a member of the F-box protein family, FBXW7 serves a role in phosphorylation-dependent ubiquitination and proteasome degradation of oncoproteins that play critical role(s) in oncogenesis. FBXW7 affects many regulatory functions involved in cell survival, cell proliferation, tumor invasion, DNA damage repair, genomic instability and telomere biology. This thorough review of current literature details how FBXW7 expression and functions are regulated through multiple mechanisms and how that ultimately drives tumorigenesis in a wide array of cell types. The clinical significance of FBXW7 is highlighted by the fact that FBXW7 is frequently inactivated in human lung, colon, and hematopoietic cancers. The loss of FBXW7 can serve as an independent prognostic marker and is significantly correlated with the resistance of tumor cells to chemotherapeutic agents and poorer disease outcomes. Recent evidence shows that genetic mutation of FBXW7 differentially affects the degradation of specific cellular targets resulting in a distinct and specific pattern of activation/inactivation of cell signaling pathways. The clinical significance of FBXW7 mutations in the context of tumor development, progression, and resistance to therapies as well as opportunities for targeted therapies is discussed VSports手机版. .
Keywords: Aneuploidy; Apoptosis; CDC4; Cancer; Cell cycle; Centrosome; Chromosome instability; Cyclin E; DNA repair; Drug resistance; Epigenetic; FBW7; FBXW7; Immunotherapy; LncRNA; MCL-1; MYC; Mutation; NOTCH; Non-coding RNA; Tumor suppressor; circRNA; miRNA V体育安卓版. .
© 2022. The Author(s).
Conflict of interest statement
Authors declare no financial conflict of interest. Dr. Nicot is an editorial board member of V体育ios版.
Figures





References
-
- Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17:115–33. - "V体育官网入口" PMC - PubMed
-
- Pelorosso FG, Balmain A. C/EBPdelta: friend or foe? a novel role for C/EBPdelta in metastasis. EMBO J. 2010;29:4063–4065. - "V体育平台登录" PMC - PubMed
Publication types
MeSH terms (VSports)
- Actions (VSports手机版)
- "VSports注册入口" Actions
- VSports最新版本 - Actions
Substances
- "VSports最新版本" Actions
Grants and funding
LinkOut - more resources
"V体育2025版" Full Text Sources
Medical
Research Materials